Achmea Investment Management B.V. Has $10.11 Million Position in United Therapeutics Corporation $UTHR

Achmea Investment Management B.V. lessened its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 36.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,105 shares of the biotechnology company’s stock after selling 13,709 shares during the period. Achmea Investment Management B.V. owned 0.06% of United Therapeutics worth $10,105,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Center For Asset Management LLC lifted its holdings in shares of United Therapeutics by 87.6% in the third quarter. Center For Asset Management LLC now owns 3,097 shares of the biotechnology company’s stock worth $1,298,000 after buying an additional 1,446 shares in the last quarter. Captrust Financial Advisors boosted its stake in United Therapeutics by 22.7% during the third quarter. Captrust Financial Advisors now owns 9,437 shares of the biotechnology company’s stock valued at $3,956,000 after buying an additional 1,744 shares during the period. Coldstream Capital Management Inc. grew its stake in United Therapeutics by 6.5% in the 3rd quarter. Coldstream Capital Management Inc. now owns 2,285 shares of the biotechnology company’s stock worth $958,000 after buying an additional 140 shares in the last quarter. Finally, Danske Bank A S purchased a new position in shares of United Therapeutics in the 3rd quarter worth about $6,703,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. HC Wainwright boosted their price objective on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Wells Fargo & Company lifted their price objective on United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. Bank of America restated a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, TD Cowen raised their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $548.09.

United Therapeutics Stock Down 1.8%

NASDAQ UTHR opened at $530.35 on Thursday. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $548.12. The business has a 50-day moving average price of $488.85 and a 200-day moving average price of $465.99. The firm has a market cap of $23.25 billion, a price-to-earnings ratio of 19.01, a price-to-earnings-growth ratio of 1.94 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company earned $6.19 EPS. Research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $502.79, for a total value of $11,312,775.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $513.18, for a total transaction of $5,644,980.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $18,875,273.58. This trade represents a 23.02% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 331,520 shares of company stock worth $162,965,343. Insiders own 10.30% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.